SNP information rs121913459

Research and publications:

  10988075   Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

  11423618   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

  11853795   BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

  11861307   Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.

  11964322   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  12130516   Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

  12399961   Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

  12623848   Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  14745431   High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

  15194504   The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

  20367437   Mutations in ABL kinase domain are associated with inferior progression-free survival.

  20537386   BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

  20963643   Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment.

  21562040   BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  21762985   Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

  21872826   Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.

  21895409   Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.

  22306673   Rapid quantitative detection of the T315I mutation in patients with chronic myelogenous leukemia.

  22772060   MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

  22870928   Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction.

  23355941   Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.

  23540562   Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.

  23676790   Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.

  24236021   Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.

  25157968   Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

  25686603   Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.